21429214

Source:http://linkedlifedata.com/resource/pubmed/id/21429214

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0023467, umls-concept:C0031809, umls-concept:C0206012, umls-concept:C0332529, umls-concept:C0544452, umls-concept:C0677908, umls-concept:C1096776, umls-concept:C1274040
pubmed:dateCreated	2011-4-15
pubmed:databankReference	http://linkedlifedata.com/resource/pubmed/xref/ClinicalTrials.gov/NCT00003991
pubmed:abstractText	Data from a randomized multinational phase 3 trial of 320 adults with acute myeloid leukemia (AML) demonstrated that maintenance therapy with 3-week cycles of histamine dihydrochloride plus low-dose interleukin-2 (HDC/IL-2) for up to 18 months significantly improved leukemia-free survival (LFS) but lacked power to detect an overall survival (OS) difference.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/21429214-12958120, http://linkedlifedata.com/resource/pubmed/commentcorrection/21429214-14599092, http://linkedlifedata.com/resource/pubmed/commentcorrection/21429214-16556892, http://linkedlifedata.com/resource/pubmed/commentcorrection/21429214-16563089, http://linkedlifedata.com/resource/pubmed/commentcorrection/21429214-17019734, http://linkedlifedata.com/resource/pubmed/commentcorrection/21429214-1792461, http://linkedlifedata.com/resource/pubmed/commentcorrection/21429214-18024861, http://linkedlifedata.com/resource/pubmed/commentcorrection/21429214-18024867, http://linkedlifedata.com/resource/pubmed/commentcorrection/21429214-18205045, http://linkedlifedata.com/resource/pubmed/commentcorrection/21429214-18285439, http://linkedlifedata.com/resource/pubmed/commentcorrection/21429214-18606980, http://linkedlifedata.com/resource/pubmed/commentcorrection/21429214-19118375, http://linkedlifedata.com/resource/pubmed/commentcorrection/21429214-20008225, http://linkedlifedata.com/resource/pubmed/commentcorrection/21429214-20338904
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/101263253
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Histamine, http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2
pubmed:status	MEDLINE
pubmed:issn	1745-6215
pubmed:author	pubmed-author:BruneMats LML, pubmed-author:BuyseMarcM, pubmed-author:CastaigneSylvieS, pubmed-author:LucchesiKathryn JKJ, pubmed-author:RoweJacob MJM, pubmed-author:SquiffletPierreP
pubmed:issnType	Electronic
pubmed:volume	12
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	86
pubmed:dateRevised	2011-7-28
pubmed:meshHeading	pubmed-meshheading:21429214-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:21429214-Chi-Square Distribution, pubmed-meshheading:21429214-Disease-Free Survival, pubmed-meshheading:21429214-Female, pubmed-meshheading:21429214-Histamine, pubmed-meshheading:21429214-Humans, pubmed-meshheading:21429214-Interleukin-2, pubmed-meshheading:21429214-Leukemia, Myeloid, Acute, pubmed-meshheading:21429214-Linear Models, pubmed-meshheading:21429214-Male, pubmed-meshheading:21429214-Middle Aged, pubmed-meshheading:21429214-Proportional Hazards Models, pubmed-meshheading:21429214-Remission Induction, pubmed-meshheading:21429214-Reproducibility of Results, pubmed-meshheading:21429214-Risk Assessment, pubmed-meshheading:21429214-Risk Factors, pubmed-meshheading:21429214-Survival Analysis, pubmed-meshheading:21429214-Survival Rate, pubmed-meshheading:21429214-Time Factors, pubmed-meshheading:21429214-Treatment Outcome
pubmed:year	2011
pubmed:articleTitle	Assessment of the consistency and robustness of results from a multicenter trial of remission maintenance therapy for acute myeloid leukemia.
pubmed:affiliation	International Drug Development Institute, Department of Biostatistics, Louvain-la-Neuve, Belgium. marc.buyse@iddi.com
pubmed:publicationType	Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase III